Approximately 40% of people living with T2D will eventually go on to develop CKD, a gradual loss of kidney function over time that affects more than 800 million people worldwide.
Previously presented at the 61st European Renal Association Congress and published in the New England Journal of Medicine, the trial compared once-weekly 1mg injectable Ozempic with placebo as an adjunct to standard of care on kidney outcomes for reducing the risk of progression of kidney impairment and the risk of kidney and cardiovascular mortality in 3,533 people living with T2D and CKD.
Results demonstrated a 24% reduction in the risk of kidney disease progression and cardiovascular and kidney mortality compared to placebo, and Ozempic 1mg demonstrated superiority to placebo for all secondary outcomes assessed, including a significant reduction in the mean annual glomerular filtration rate.
In addition, the risk of major cardiovascular events and the risk of death were significantly lower in the Ozempic group, with fewer serious adverse events reported compared to the placebo group.
After a median follow-up of just over three years, Novo stopped the FLOW study due to the efficacy of Ozempic in preventing kidney disease-related incidences and submitted a label extension application, which was accepted for review by the US Food and Drug Administration, with a decision anticipated in January 2025.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.